NASDAQ:GRAL 3 October 2025 - 27 February 2026

GRAIL shares fell 5.9% to $54.70 in premarket trading Friday, reversing part of Thursday’s 12.2% gain. The moves follow a U.K. NHS trial update last week that missed its main goal for the Galleri cancer blood test. Investors await management’s presentation at the TD Cowen conference in Boston on March 3.

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.